Montelukast-loaded nanostructured lipid carriers: Part II Pulmonary drug delivery and in vitro-in vivo aerosol performance

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 88, Issue 1, 2014, Pages 169-177

  Patil Gadhe, Arpana ^a,b   Kyadarkunte, Abhay ^a,b   Patole, Milind ^b   Pokharkar, Varsha ^a  

^a BHARATI VIDYAPEETH DEEMED UNIVERSITY   (India)

^b NATIONAL CENTRE FOR CELL SCIENCE   (India)

Author keywords

A549 cell line; Cascade impactor; Dry powder for inhalation (DPI); Lipid nanoparticles; Montelukast sodium; Pulmokinetic parameters

Indexed keywords

ACETIC ACID DERIVATIVE; AEROSOL; CAPRYOL PROPYLENE GLYCOL MONOCAPRYLATE; DIACYLGLYCEROL; GLYCEROL PALMITOSTEARATE; LIPID; MONTELUKAST; NANOPARTICLE; POLYMER; POWDER; PROPANEDIOL DERIVATIVE; QUINOLINE DERIVATIVE;

ADMINISTRATION AND DOSAGE; AEROSOL; ANIMAL; CHEMISTRY; DRUG DELIVERY SYSTEM; DRUG EFFECTS; DRY POWDER INHALER; HUMAN; INHALATIONAL DRUG ADMINISTRATION; LUNG; MALE; PARTICLE SIZE; POWDER; RAT; TUMOR CELL LINE; WISTAR RAT;

ACETATES; ADMINISTRATION, INHALATION; AEROSOLS; ANIMALS; CELL LINE, TUMOR; DIGLYCERIDES; DRUG DELIVERY SYSTEMS; DRY POWDER INHALERS; HUMANS; LIPIDS; LUNG; MALE; NANOPARTICLES; PARTICLE SIZE; POLYMERS; POWDERS; PROPYLENE GLYCOLS; QUINOLINES; RATS; RATS, WISTAR;

EID: 84934268314     PISSN: 09396411     EISSN: 18733441     Source Type: Journal    
DOI: 10.1016/j.ejpb.2014.07.007     Document Type: Article

References (60)

1. H.A. Boushey Drugs used in asthma B.G. Katzung, S.B. Masters, A.J. Trevor, Basic and Clinical Pharmacology twelfth ed. 2012 McGraw-Hill/Lange Medical USA
2. S.E. Dahlen Treatment of asthma with antileukotrienes: first line or last resort? Eur. J. Pharmacol. 533 2006 40 56
3. W. Busse, and M. Kraft Cysteinyl leukotrienes in allergic inflammation: strategic target for therapy Chest 127 2005 1312 1326
4. P. Bradding Mast cell regulation of airway smooth muscle function in asthma Eur. Respir. J. 29 2007 827 830
5. T.S. Hallstand, and W.R. Henderson Jr An update on the role of leukotrienes in asthma Curr. Opin. Allerg. Clin. Immunol. 10 2010 60 66
6. C.G. Lofdahl, T.F. Reiss, J.A. Leff, E. Israel, M.J. Noonan, A.F. Finn, B.C. Seidenberg, T. Capizzi, S. Kundu, and P. Godard Randomised, placebo controlled trial of effect of a leukotriene receptor antagonist, montelukast, on tapering inhaled corticosteroids in asthmatic patients BMJ 319 1999 87 90
7. P. Montuschi Role of Leukotrienes and Leukotriene Modifiers in Asthma Pharmaceuticals 3 2010 1792 1811
8. K.M. Gross, and C.D. Ponten New strategies in the medical management of asthma Am. Fam. Physician 58 1998 89 100
9. J.P. Kemp, R.J. Dockhorn, and G.G. Shapiro Montelukast J. Allerg. Clin. Immunol. 99 1997 S321-S321
10. R. Ramakrishnan, E. Migoya, and B. Knorr A population pharmacokinetic model for montelukast disposition in adults and children Pharm. Res. 22 2005 532 540
11. E. Migoya, L. Kearns, A. Hartford, J. Zhao, C.A. Tozzi, B. Knorr, and P. Deutsch Pharmacokicetics of montelukast in asthmatic patients 6 and 24 months old J. Clin. Pharmacol. 44 2004 487 494
12. W. Storms Update on montelukast and its role in the treatment of asthma, allergic rhinitis and exercise-induced bronchoconstriction Expert Opin. Pharmacother. 8 2007 2173 2187
13. F.M. de Benedictis, S. Vaccher, and D. de Benedictis Montelukast sodium for exercise-induced asthma Drugs Today (Barc) 44 2008 845 855
14. A. Nayak, and R.B. Langdon Montelukast in the treatment of allergic rhinitis: an evidence-based review Drugs 67 2007 887 901
15. J.P. Seale Chemical targeting of drug therapy in asthma and airways disease Adv. Drug Deliv. Rev. 5 1990 73 92
16. J.J. Zhao, J.D. Rogers, S.D. Holland, P. Larson, R.D. Amin, R. Haesen, A. Freeman, M. Seiberling, M. Merz, and H. Cheng Pharmacokinetics and bioavailability of montelukast sodium (MK-0476) in healthy young and elderly volunteers Biopharm. Drug Dispos. 18 1997 769 777
17. H. Bisgaard Pathophysiology of the cysteinyl leukotrienes and effects of leukotriene receptor antagonists in asthma Allergy 56 2001 7 11
18. S. Cryan, N. Sivadas, and L. Garcia-Contreras In vivo animal models for drug delivery across the lung mucosal barrier Adv. Drug Deliv. Rev. 59 2007 1133 1151
19. M. Beck-Broichsitter, T. Schmehl, W. Seeger, and T. Gessler Evaluating the controlled release properties of inhaled nanoparticles using isolated, perfused, and ventilated lung models J. Nanomater. 2011 (Article ID 163791)
20. J.S. Patton, C.S. Fishburn, and J.G. Cheers The lung as a portal of entry for systemic drug delivery Proc. Am. Thorac. Soc. 14 2004 338 344
21. G. Taylor, and I. Kellaway Pulmonary drug delivery A.M. Hillery, A.W. Lloyd, J. Swarbrick, Drug delivery and Targeting 2001 Taylor & Francis London, UK 244
22. M.P. Timsina, G.P. Martin, C. Marriott, D. Ganderton, and M. Yianneskis Drug delivery to the respiratory tract using dry powder inhalers Int. J. Pharm. 101 1994 1 13
23. J. Heyder Deposition of inhaled particles in the human respiratory tract and consequences for regional targeting in respiratory drug delivery Proc. Am. Thorac. Soc. 14 2004 315 320
24. P.J. Davies, G.W. Hanlon, and A.J. Moluneux An investigation into the deposition of inhalation aerosol particles as a function of airflow rate in a modified 'Kirk lung' J. Pharm. Pharmacol. 28 1976 908 911
25. D.C. Thompson Pharmacology of therapeutic aerosols A.J. Hickey, Pharmaceutical Inhalation Aerosol Technology second ed. 2004 Marcel Dekker New York, USA
26. S. Weber, A. Zimmer, and J. Pardeike Solid Lipid Nanoparticles (SLN) and Nanostructured Lipid Carriers (NLC) for pulmonary application: a review of the state of the art Eur. J. Pharm. Biopharm. 86 2014 7 22
27. A. Patil-Gadhe, and V. Pokharkar Single step spray drying method to develop proliposomes for inhalation: a systematic study based on quality by design approach Pulm. Pharmacol. Ther. 27 2014 197 207
28. R. Pandey, and G.K. Khuller Solid lipid particle-based inhalable sustained drug delivery system against experimental tuberculosis Tuberculosis 85 2005 227 234
29. R. Yang, S. Yang, W. Shim, F. Cui, G. Cheng, I. Kim, D. Kim, S. Chung, and C. Shim Lung-specific delivery of paclitaxel by chitosan-modified PLGA nanoparticles via transient formation of microaggregates J. Pharm. Sci. 98 2009 970 984
30. W. Rojanarat, N. Changsan, E. Tawithong, S. Pinsuwan, H.K. Chan, and T. Srichana Isoniazid proliposomes powders for inhalation-preparation, characterization and cell culture studies Int. J. Mol. Sci. 12 2011 4414 4434
31. N. Payne, P. Timmins, C.V. Ambrose, M.D. Ward, and F. Ridgway Proliposomes: a novel solution to an old problem J. Pharm. Sci. 75 1986 325 333
32. K.H. Song, S.J. Chung, and C.K. Shim Preparation and evaluation of proliposomes containing salmon calcitonin J. Contr. Release 84 2002 27 37
33. K. Westesen Novel lipid based colloidal dispersions as potential drug administration systems-expectations and reality Colloid Polym. Sci. 278 2000 608 618
34. C.J. Hitzman, W.F. Elmquist, L.W. Wattenberg, and T.S. Wiedmann Development of a respirable, sustained release microcarrier for 5-fluorouracil I: in vitro assessment of liposomes, microspheres, and lipid coated nanoparticles J. Pharm. Sci. 95 2006 1114 1126
35. W. Mehnert, and K. Mader Solid lipid nanoparticles: production, characterization and applications Adv. Drug Deliv. Rev. 47 2001 165 196
36. W.H.D. Jong, and P.J.A. Borm Drug delivery and nanoparticles: applications and hazards Int. J. Nanomed. 3 2008 133 149
37. S. Mallick Outcome of patients with idiopathic pulmonary fibrosis (IPF) ventilated in intensice care unit Respir. Med. 102 2008 1355 1359
38. D.A. Zisman, M.P. Keane, J.A. Belperio, R.M. Strieter, and J.P. Lynch Pulmonary fibrosis Methods Mol. Med. 117 2005 3 44
39. P.U. Singare, and J.D. Mhatre Cationic surfactants from arginine:synthesis and physicochemical properties Am. J. Chem. 2 2012 186 190
40. Y.F. Luo, D.W. Chen, L.X. Ren, X.L. Zhao, and J. Qin Solid lipid nanoparticles for enhancing vinpocetine's oral bioavailability J. Control. Rel. 114 2006 53 59
41. Y. Son, and J.T. McConville Development of a standardized dissolution test method for inhaled pharmaceutical formulations Int. J. Pharm. 382 2009 15 22
42. N.M. Davies, and M.R. Feddah A novel method for assessing dissolution of aerosol inhaler products Int. J. Pharm. 255 2003 175 187
43. G. Philip, A. Pedinoff, K. Vandormael, M.S. Tymofyeyev, S.S. Smugar, T.F. Reiss, and P.E. Korenblat A phase I randomized, placebo-controlled, dose-exploration study of single-dose inhaled montelukast in patients with chronic asthma J. Asthma 47 2010 1078 1084
44. K.N. Raju, T.G. Swamy, and A.L. Rao Development and validation of RP-HPLC method for the determination of montelukast sodium in bulk and in pharmaceutical formulation Int. J. Pharm. Chem. Biol. Sci. 1 2011 12 16
45. J. Pardeike, S. Weber, T. Haber, J. Wagner, H.P. Zarfl, H. Plank, and A. Zimmer Development of an Itraconazole-loaded nanostructured lipid carrier (NLC) formulation for pulmonary application Int. J. Pharm. 419 2011 329 338
46. M.N. Padamwar, and V.B. Pokharkar Development of vitamin loaded topical liposomal formulation using factorial design approach: drug deposition and stability Int. J. Pharm. 320 2006 37 44
47. S. Honary, and F. Zahir Effect of zeta potential on the properties of nano-drug delivery systems - a Review Part 1 Tro. J. Pharm. Res. 12 2013 255 264
48. S. Honary, and F. Zahir Effect of zeta potential on the properties of nano-drug delivery systems - a review Part 2 Tro. J. Pharm. Res. 12 2013 265 273
49. J. Cain An alternative technique for determining ANSI/CEMA standard 550 flowability ratings for granular materials Powder Hand. Proc. 14 2002 218 220
50. H. Steckel, and G.G. Brandes A novel spray-drying technique to produce low density particles for pulmonary delivery Int. J. Pharm. 278 2004 187 195
51. A.H. Chow, H.H. Tong, P. Chattopadhyay, and B.Y. Shekunov Particle engineering for pulmonary drug delivery Pharm. Res. 24 2007 411 437
52. P. Costa, and J.M.S. Lobo Modeling and comparison of dissolution profiles Eur. J. Pharm. Sci. 13 2001 123 133
53. W.H. Finlay, K.W. Stapelton, and P. Zuberbuhler Fine particle fraction as a measure of mass depositing in the lung during inhalation of nearly isotonic nebulized aerosols J. Aerosol Sci. 28 1997 1301 1309
54. H.S. Rahman, A. Rasedee, C.W. How, A.B. Abdul, N.A. Zeenathul, H.H. Othman, M.I. Saeed, and S.K. Yeap Zerumbone-loaded nanostructured lipid carriers: preparation, characterization, and antileukemic effect Int. J. Nanomedicine 8 2013 2769 2781
55. M. Andrade-Lima, L.F.F. Pereira, and A.L.G. Fernandes Pharmaceutical equivalence of the combination formulation of budesonide and formoterol in a single capsule with a dry powder inhaler J. Bras. Pneumol. 38 2012 748 756
56. P.R. Byron, and J.S. Patton Drug delivery via the respiratory tract J. Aerosol Med. 7 1994 49 75
57. P.A. Jaques, and C.S. Kim Measurement of total lung deposition of inhaled ultrafine particles in healthy men and women Inhal. Toxicol. 12 2000 715 731
58. S. Schurch, P. Gehr, V.I. Hof, M. Geiser, and F. Green Surfactant displaces particles toward the epithelium in airways and alveoli Respir. Physiol. 80 1990 17 32
59. F.J. Bhavna, G. Ahmad, G.K. Mittal, G. Jain, R.K. Malhotra, and A. Khar Bhatnagar Nano-salbutamol dry powder inhalation: a new approach for treating broncho-constrictive conditions 71 2009 282 291
60. J.M. Lauweryns, and J.H. Baert Alveolar clearance and the role of the pulmonary lymphatics Am. Rev. Respir. Dis. 115 1977 625 683